Application Note: An Easy-to-Use Assay to Measure Target Cell Death by Antibody Dependent Cellular Phagocytosis (ADCP)
With an increasing industry focus on antibody drugs, there is an ever greater need for functional bioassays that interrogate the various mechanisms of action (MOA) for the therapeutic antibody…
The most common human immunoglobulin isotype used for therapeutic intervention is IgG1, which contains two antigen-binding Fab arms and an Fc region. This Fc domain of IgG1 can bind to Fcγ receptors expressed on immune effector cells and mediate target cell death by various mechanisms such as Complement Dependent Cytotoxicity (CDC), Antibody Dependent Cell-Mediated Cytotoxicity (ADCC), and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP).
Regulatory authorities are now commonly requiring data on the impact of each of these effectormediated MOAs for each submitted antibody therapeutic. There are a number of available ways to measure these effector-mediated MOAs, however getting a reproducible true measure of ADCP, in particular, has been quite challenging.
Related content from this organisation
- Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option
- Implementing ADCC assays in QC: When donor variability isn’t an option
- Drug Target Review – Issue #3 2017
- Skin toxicity mechanisms associated with mGluR5 negative allosteric modulators
- The mast cell receptor MrgX2 and drug-induced anaphylaxis